Alterations of the murine gut microbiome in allergic airway disease are independent of surfactant protein D by Barfod, Kenneth K et al.
Syddansk Universitet
Alterations of the murine gut microbiome in allergic airway disease are independent of
surfactant protein D
Barfod, Kenneth K; Roggenbuck, Michael; Al-Shuweli, Suzan; Fakih, Dalia; Sørensen, Søren
J.; Sørensen, Grith Lykke
Published in:
Heliyon
DOI:
10.1016/j.heliyon.2017.e00262
Publication date:
2017
Document version
Final published version
Document license
CC BY
Citation for pulished version (APA):
Barfod, K. K., Roggenbuck, M., Al-Shuweli, S., Fakih, D., Sørensen, S. J., & Sørensen, G. L. (2017). Alterations
of the murine gut microbiome in allergic airway disease are independent of surfactant protein D. Heliyon, 3(3),
[e00262]. DOI: 10.1016/j.heliyon.2017.e00262
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Apr. 2017
Alterations of the murine gut
microbiome in allergic airway
disease are independent of
surfactant protein D
Kenneth K. Barfod a,1,*, Michael Roggenbuck b,1, Suzan Al-Shuweli a, Dalia Fakih c,d,
Søren J. Sørensen b, Grith L. Sørensen c
aNational Research Centre for the Working Environment, Lersø Parkallé 105, 2100 Copenhagen O, Denmark
bUniversity of Copenhagen, Department of Biology, Microbiology, Universitetsparken 15, 2100 Copenhagen O,
Denmark
cDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern
Denmark, Odense, Denmark
d Laboratory of Immunology, Faculty of public health, Lebanese University, Fanar, Lebanon
*Corresponding author.
E-mail addresses: kkb@nrcwe.dk (K.K. Barfod), MIRO@novozymes.com (M. Roggenbuck).
1 These authors contributed equally to this work.
Abstract
Background: SP-D is an important host defense lectin in innate immunity and SP-D
deficient mice show several abnormal immune effects and are susceptible to allergen-
induced airway disease. At the same time, host microbiome interactions play an
important role in the development of allergic airway disease, and alterations to gut
microbiota have been linked to airway disease through the gut-lung axis. Currently, it
is unknown if the genotype (Sftpd-/- or Sftpd+/+) of the standard SP-D mouse model
can affect the host microbiota to such an degree that it would overcome the cohousing
effect on microbiota and interfere with the interpretation of immunological data from
the model. Generally, little is known about the effect of the SP-D protein in itself and
in combination with airway disease on the microbiota. In this study, we tested the
hypothesis that microbiome composition would change with the lack of SP-D protein
and presence of allergic airway disease in the widely used SP-D-deficient mouse
model.
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Results: We describe here for the first time the lung and gut microbiota of the SP-D
mouse model with OVA induced allergic airway disease. After the challenge animals
were killed and fecal samples were taken from the caecum and lungs were subjected
to bronchoalveolar lavage for comparison of gut and lungmicrobiota by Illumina 16S
rRNA gene sequencing. A significant community shift was observed in gut
microbiota after challenge with OVA. However, the microbial communities were not
significantly different between SP-D deficient and wild type mice from the same
cages in either naïve or OVA treated animals. Wild type animals did however show
the largest variation between mice.
Conclusions: Our results show that the composition of the microbiota is not
influenced by the SP-D deficient genotype under naïve or OVA induced airway
disease. However, OVA sensitization and pulmonary challenge did alter the gut
microbiota, supporting a bidirectional lung-gut crosstalk. Future mechanistic
investigations of the influence of induced allergic airway disease on gut microbiota
are warranted.
Keywords: Microbiology, Immunology
1. Background
Surfactant protein-D (SP-D) belongs to the collectin family of host defense
proteins. SP-D is produced by alveolar type II cells in the lung, but is further
widely distributed on mucosal surfaces of the body, including the gastrointestinal
epithelium [1, 2]. SP-D functions are mainly studied in the lungs. The protein is
involved in pulmonary immunity due to lysis, opsonization, neutralization,
agglutination, complement activation, enhanced phagocytosis of diverse microbes
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13] and the SP-D deficient (Sftpd-/-) lung is
characterized with inflammatory and structural lung changes resulting in altered
lung mechanics [14, 15, 16]. Moreover, airway inflammation and allergic asthma
is associated with increases in SP-D levels in bronchoalveolar lavage fluids, tissue,
and blood in animal models as well as in human patients, linking SP-D to disease
responses [17]. Likewise, induced allergic airway disease in Sftpd-/- mice
moderately increases the allergic phenotype [18, 19, 20, 21]. In contrast, it is
largely unexplored which functions SP-D may have in the intestine, although
epithelial uptake of pathogenic bacteria [22] and a disease-modifying role in
inflammatory bowel disease is suggested [23, 24].
Novel culture independent techniques for microbial identification have in short of a
decade changed the way we view the importance of the microbes that inhabits our
bodies. Unique host microbiomes have been associated to priming of the immune
system and the development of inflammatory diseases such as asthma, chronic
obstructive pulmonary disease (COPD), Crohnś disease, diabetes or obesity [25,
26, 27, 28]. The perinatal priming and development of the microbiome and the
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putative gut-lung axis have been strongly associated with the development of
allergy and asthma [29, 30, 31]. Several animal models have been used to shed
light on the mechanisms, although most studies show no evidence of a direct causal
effect [32, 33, 34]. Some studies have used fecal transplants to germ-free mice or
cross-fostering models in order to show that the pathogenic phenotypes can be
ascribed to the gut microbiome [35, 36, 37, 38]. Recently it has been shown that
also the lungs harbor complex communities of bacteria in healthy as well as
diseased states, which might contribute to pathogenesis [39, 40, 41, 42, 43].
Although, there appear to be a link between inflammatory diseases in the
respiratory and intestinal systems, there have been surprisingly few experimental
studies investigating a possible cross talk [44, 45]. The most recent major study
demonstrate that parasite induced changes in intestinal microbiota leading to
changes in the synthesis of anti-inflammatory short chain fatty acids (SCFAs),
which have the propensity to dampen development of allergic asthma [46]. On the
other hand, allergic asthma may influence the composition of intestinal microbiota
as previously demonstrated [40]. Recently we have shown that induction of OVA-
induced allergic airway disease itself had a profound effect on the lung microbiome
in a vitamin D deficient mouse (BALB/cJ) model [47].
The role of SP-D in regulation of the gut and lung microbiome composition in the
setting of pulmonary allergy has not previously been investigated. In this study, we
investigate for the first time microbiota of Sftpd−/− and Sftpd+/+ mice, in
ovalbumin (OVA) induced airway allergy using Illumina 16S rRNA gene
sequencing.
2. Results
We have used NGS 16S rRNA gene sequencing to describe lung and gut
microbiota of the SP-D mouse model under OVA induced allergic airway disease.
2.1. Sequence quality and overall microbial communities
After sequence retrieval and initial data treatment 869802 reads were divided into
697 Operational taxonomic units (OTUs) with a median sequence distribution of
13685 sequences per sample. The caecal samples contained primarily Firmicutes,
Bacteroidetes, Proteobacteria and minor occurrence of Tenericutes as well as
Deferribacteres (Fig. 1). In the broncho-alveolar lavage (BAL) fluids the bacterial
community were composed of Actinobacteria, Firmicutes, Proteobacteria and
Bacteroidetes together with Fusobacteria as previously observed in other mouse
strains and studies [32, 48].
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2.2. The microbial communities do not change with the SP-D
deficiency but OVA sensitization and lung challenge alters
caecum community composition
As demonstrated previously, OVA sensitization and challenge induced an allergic
phenotype in the C57BL6 N mice with more pronounced mucous cell metaplasia in
Sftpd-/- mice compared to Sftpd+/+ littermates [21]. In order to elude microbial
differences between microbiotas according to genotypes and airway disease
treatments, we compared the number of OTUs found in the samples. Fig. 2 shows
the number of observed OTUs from all our experimental groups and variation
between samples (alpha diversity). The number of OTUs in caecal samples were 2
fold higher than OTU numbers found in the lungs (Wilcoxon test, p < 0.001).
There were no differences in OTU levels between genotype or treatments in either
the caecum or lung.
We also investigated how different OTUs are distributed among all samples (beta
diversity) (Fig. 3) and in caecal samples only. All the caecum samples cluster
together completely separated from the lung and the SP-D deficient genotype did
not discriminate between samples. The naive wildtype (Sftpd+/+) gut microbiota
did have the statistical significant largest bacterial variation, compared to both
naïve Sftpd-/- and allergic airway disease groups (Kruskal-Wallis test, P-value =
1.32e-07) (Fig. 4).
[(Fig._1)TD$FIG]
Fig. 1. The overall phyla composition in caecal and BAL samples from individual C57BL/6 N female
Sftpd+/+ and Sftpd-/- mice. Fig. 1 shows the phyla composition on the Y-axis as relative abundance.
The 34 samples are clustered along the X-axis according to similarity between samples. The BAL
samples are BLUE and the caecal samples are GREEN (OVA treated animals n = 16) or RED (for
unchallenged animals n = 18). At the bottom, sample genotype is noted either Sftpd−/-, or Sftpd+/+,
which shows no clustering. The caecal samples contained primarily Firmicutes, Bacteroidetes,
Proteobacteria and minor occurrence of Tenericutes as well as Deferribacteres. In the BAL the
bacterial community were composed of Actinobacteria, Firmicutes, Proteobacteria and Bacteroidetes
together with Fusobacteria.
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The gut microbiotas from OVA treated mice cluster together (Fig. 3), slightly
separate from the control animals, regardless of genotype in a statistical significant
manner (Anoism R = 0.100, p = 0.038). So, we investigated which OTUs from the
gut microbiota that discriminated between control and OVA sensitized and
challenged mice. The heatmap in Fig. 5 shows the primary bacterial species in
ceacum samples with an average frequency >5%. The primary differences lie
[(Fig._2)TD$FIG]
Fig. 2. Bacterial richness. Relative observed OTUs in BAL and caecum from different experimental
groups. The number of OTUs relative to each other from the different experimental groups at even
sequencing depth with added variation bars. There is a significantly more OTUs in caecum samples
regardless of mouse genotype and treatment compared to OTUs from BAL samples from OVA treated
mice (Wilcoxon test, p < 0.001).
[(Fig._3)TD$FIG]
Fig. 3. Microbial community clustering among experimental groups. Fig. 3 shows a non-metric
multidimensional scaling (NMDS) plot of the beta diversity of all the individual samples regardless of
genotype. There is a strong statistical significant dissimilarity between BAL (Blue n = 16) and caecum
samples (Red n = 16 and Green n = 18) using the Anoism test (R = 0.898, p = 0.001). There is also a
statistical significant difference between caecum samples from OVA treated animals (Green) and non-
challenges animals (Red) (R = 0.100, p = 0.038).
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within the OTUs from bacterial family of Lachnospiraceae, but also species within
family Ruminococcaceae and the genus of Helicobacteraceae contribute.
2.3. The lung microbiota under OVA conditions
The lung microbiota (Fig. 6) is clearly separate from the gut as seen in Fig. 1,
Fig. 2 and Fig. 3. But there was no clustering in beta diversity (Fig. 7) of the lung
microbiota according to SP-D-genotype. This was confirmed by the Anosim test (R
= 0.03304, = 0.322) (Fig. 8). We also tested how different the BAL samples are
within each genotype. The comparison of similarities between knockout and wild
type samples, shows that there is no statistical difference between groups
(Wilcoxon test, p > 0.05)
There was no difference in similarities within genotypes (Wilcoxon test, p > 0.05)
(Fig. 9).
Finally, we compared the most common bacterial OTUs observed in the lung
microbiotas (Fig. 6). Even though beta diversity does not discriminate between the
SP-D genotypes in the lung microbiota there are still some differences in OTUs
[(Fig._4)TD$FIG]
Fig. 4. SP-D gut microbiota samples are more variable. Fig. 4 shows the Bray Curtis distance, which
describes how different the caecum samples are within each experimental group compared to knockout
naïve animals. (OVA- Sftpd −/-) and OVA treated groups (OVA+ Sftpd−/-, OVA Sftpd+/+), wild type
(OVA- Sftpd+/+) animals without OVA exposure have the largest variation between mice (Kruskal-
Wallis test, P-value = 1.32e-07).
Article No~e00262
6 http://dx.doi.org/10.1016/j.heliyon.2017.e00262
2405-8440/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
primarily at family level. The heatmap reveals differences in several biological
relevant phylogroups such as Staphylococcus, Lactobacillus and Bifidobacterium.
3. Discussion
Our study presents the first description of the murine microbiome in SP-D deficient
model with induced allergic airway disease using NGS 16S rRNA gene
sequencing. Based on known differences in the innate immune system of the
Sftpd-/- mouse, our original hypothesis was that lack of SP-D protein could infer
alterations in microbiota able to overcome the co-housing effect. In the SP-D-
deficient model the mice are bred from heterozygous parents all genotypes mixed
and co-housed. A significant community shift in gut microbiota was observed after
challenge with OVA compared to naïve mice, but the microbial communities of the
cohoused mice were not significantly different according to mouse genotype. The
[(Fig._5)TD$FIG]
Fig. 5. Primary observed bacterial species in the gut summarized by treatments. Fig. 5 shows a heatmap
of the primary bacterial species (>5% relative frequency) summarized by treatment. The OVA
treatments only are significantly different from naïve animal (R = 0.100, p = 0.038). The primary
differences lies within the OTUs from bacterial family of Lachnospiraceae.; Shown are OTUs with an
average frequency > 5%. Data was log-transformed. Non-challenged animals (OVA-) and OVA treated
animals (OVA+).
Article No~e00262
7 http://dx.doi.org/10.1016/j.heliyon.2017.e00262
2405-8440/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
answer to this question is very important since any genotype specific microbiota
changes in themselves could have an impact on the outcome of inflammatory
disease experiments in the SP-D model and influence the analysis. We have
previously shown that OVA treatment in itself has a clear impact on the lung
microbiota in wildtype BALB/cJ mice [47].
Our results on gut microbiota show that the naïve wild type has the largest
variation in OTUs within the experimental groups. This could indicate that OVA-
sensitization and challenge that induce inflammation also reduces variation in
microbiota composition. It is worth noting that there were only mild allergic
differences between OVA-sensitized and challenged Sftpd+/+ and Sftpd−/-, [21]
making it possible to separate the effects of SP-D and allergy on the gut
microbiota.
[(Fig._6)TD$FIG]
Fig. 6. Lung microbiota summarized by genotype. Fig. 6 shows bacterial species distribution
distinguished between Sftpd −/- and Sftpd +/+ from BAL samples. Most common bacterial OTUs
observed in average above 5% (Data are log-transformed) There is no statistical significant clustering
between genotypes samples based on the meta data in the BAL samples confirmed by the anosim test
R = 0.03304, = 0.322.
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The lung microbiotas of OVA sensitized and challenged animals cluster
completely separate from the gut, with significantly lower numbers of OTUs per
sample. There was no difference in similarities between genotypes in the OVA
sensitized and challenged animals. This aligns with previous observations from
analysing the unchallenged lung microbial community of Sftpd-/- and Sftpd+/+
mice with the faster but less sensitive DGGE method [21]. A strength of this study
would have been to have compare BAL samples from both sexes of naïve animals
to those of OVA challenged mice with 16S rRNA gene sequencing. We have
[(Fig._7)TD$FIG]
Fig. 7. Cluster analysis of the beta variation between caecal samples. Fig. 7 shows beta variation
between all caecum samples based on OVA treatment and genotype. There are no statistical significant
differences of the bacterial communities between genotypes in either treatment group using anoism.
(OVA- Sftpd−/- VS. OVA- Sftpd+/+, R = -0.018, P = 0.541) (OVA+ Sftpd +/+ VS. OVA + Sftpd −/-,
R = −0.06614, P = 0.709).
[(Fig._8)TD$FIG]
Fig. 8. Cluster analysis of the beta variation between BAL samples. Fig. 8 shows beta variation
between BAL samples according to genotype. There is no statistical significant clustering between the
BAL samples based on the Sftpd −/- or Sftpd +/+ using meta data in the BAL samples confirmed by the
Anosim test R = 0.03304, = 0.322.
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previously shown that DGGE is suitable to analyse microbial shifts and sex
dependency in lung microbiota [49]. Sex difference in lung microbiota, under
OVA allergy and control conditions, is thus an example of a difference capable of
overcoming co-housing effects [47].
The primary intestinal bacterial differences in our experiments between OVA and
unchallenged mice are found within the OTUs from bacterial family of
Lachnospiraceae, which are commonly found in the GI-tract of mammals
including humans, where they participate in the production of SCFAs [50]. A
change in SCFA producing species in the gut can influence local allergic
inflammation in the lung, possibly in a bi-directional manner [51]. The gut-lung
crosstalk is mediated through primed regulatory T-cells (T-regs) [52, 53]. Such
observation were recently supported by studies demonstrating that gut microbiota
modulated by the presence of intestinal helminths, increases in SCFA producing
species and SCFA production and that transfer of the modulated gut microbiota in
itself can mediate protection against induced allergic asthma in mice [46]. The
opposite direction of effects is less well explored. However, recent results obtained
using airway LPS administration or the house dust mite (HDM) model of allergic
airway disease in mice showed that the resulting lung inflammation changed the
bacterial composition of the gut [40, 54]. Our results are in support of those
previous data and suggest that pulmonary inflammation can alter the composition
of the gut microbiome through yet unidentified pathways.
[(Fig._9)TD$FIG]
Fig. 9. Bray-Curtis dissimilarity between BAL samples according to genotype. Fig. 9 shows how
different the BAL samples are within each genotype. The comparison of similarities within the BAL
groups samples (Sftpd −/- = Knockout, Sftpd +/+ = wild type) shows that there is no difference
(Wilcoxon test, p > 0.05).
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4. Conclusions
The SP-D deficient genotype does not cause alterations to the microbiota that
interfere with the use of the SP-D deficient mice for immunological research. The
genotype does not significantly alter intestinal microbiotas in control conditions or
either lung or gut microbiotas in OVA induced allergic airway disease. However,
OVA sensitization and pulmonary challenge, does alter the composition of gut
microbiota, supporting a previously reported bidirectional lung-gut crosstalk in a
HDM allergy model. The data supports that lung, and cecal microbiotas are very
dynamic that the gut-lung microbial axis is bi-directional. Investigations of cross
talk and mechanistic effects of induced allergic airway disease on intestinal
microbiota are warranted.
5. Methods
5.1. Mouse model
Six- to 8-weeks old C57BL/6 N female Sftpd+/+ and Sftpd-/- [14] littermate mice
were bred from Sftpd+/− heterozygous parents [21]. They were co-housed in the
animal house at the University of Southern Denmark with access to pelleted food
and water ad libitum. Test for zygosity was performed on tail biopsies of 3-week-
old mice using the REDExtract-N-AmpTM Tissue PCR Kit (Sigma-Aldrich)
according to the manufacturer’s instructions. SP-D genotypes were identified by
multiplex PCR using the 5′-GGTTTCTGAGATGGGAGTCGTG-3′ as the forward
p r i m e r , a n d 5 ′T G GGG CAG T GGA T GGAG T G T G C - 3 ′ a n d
5′GTGGATGTGGAATGTGCGAG-3′ reverse recognizing the wild-type allele
and the Sftpd-deficient alleles, respectively.
All animal experiments are in accordance with Council of Europe Convention
European Treaty series 123 and the Danish Animal Experimentation Act (LBK
1306 of 11.21.2007). All protocols and procedures were approved by the Danish
Animal Experiments Inspectorate procedures (ref. no. 2012-15-2934-00525)
5.2. OVA induced allergic airway disease
Sftpd+/+ and Sftpd-/- mice were randomized into two experimental groups: OVA
(n = 16) and control groups (n = 18). Mice were sensitized on day 0 and day 7,
received 50 μl PBS intranasally on day 12 and day 13, challenged on days 14–16
and sacrificed on day 17. For sensitization of the OVA group, 20 μg OVA
precipitated with 2 mg alum in 200 μl PBS was administered by intraperitoneal
injection. Mice were then challenged by intranasal administration of 20 μg OVA in
50 μl PBS under light isoflurane anesthesia [21]. The control group was sensitized
with alum in PBS and challenged with PBS instead of OVA.
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5.3. Bronchoalveolar lavage (BAL)
BAL was performed with 0.5 ml of sterile PBS and gently aspirating back and
forth after 30 s (4 times). After centrifugation at 825 g for 10 min at 4 °C, the cell
free supernatant was stored at −80 °C for bacterial analysis. If recovered BAL was
less than 75% of the original PBS, it was excluded.
5.4. Sampling and DNA extraction
Caecum samples were taken from the animals last to avoid cross contamination.
The caecum was cut open and approximately 50 mg stool was removed using
sterile plastic loops directly into cryo tubes and snap frozen in liquid nitrogen.
DNA extractions from frozen caecal samples was done using Qiagen spin protocol
for detection of pathogens from stool (Qiagen, DNA mini stool kit Denmark) and
frozen cell free BAL samples were done using Qiagen spin protocol (Qiagen, DNA
mini kit Denmark) as previously described [48].
5.5. Microbiome analysis
DNA extract (5 ng) was used to generate a 466 bp long amplicon fragment using
the prokaryotic universal primer of 341F (5′-CCTAYGGGRBGCASCAG-3′) and
the 806R (5′-GGACTACNNGGGTATCTAAT-3′). The PCR reaction mix (25 μl)
contained 1 μl (12.5 μM) of each primer, 5 μl (5x) of the Phusion HF Buffer
(Finnzymes, Vantaa, Finland), 0.5 μl (10 mM) of dNTPs, 0.25 μl of the (0.5 Units)
Phusion DNA polymerase (Finnzymes, Vantaa, Finland) together with 1 μl
template and 16.25 μl sterile Sigma water. Target fragments were amplified using
the following conditions: 98 °C for 30 s, followed by 30 cycles of 98 °C for 5 s,
56 °C for 30 s and 60 °C for 1 min and a final extension of 72 °C for 5 min. In a
second PCR round, sequencing adaptors and barcodes were attached to the
amplicons under the same reaction condition as above with a lowered cycle
number of 15. Furthermore the PCR products were purified and cleaned using
Agencourt AMPure XP beads. After pooling the normalized amplicon libraries,
sequences were generated with the MiSeq 2 × 250 Nextera KIT v2 cartridge
(Illumina).
The generated sequences were first de-multiplexed and paired followed by a primer
truncation and low quality removal step using the default setting of the Uparse
pipeline [55]. Chimeric sequences were discovered with Uchime and disregarded
[56]. Afterwards, OTUs were picked with Usearch at 97% sequence identity [57] and
classified using Mothur (v.1.33.3) and the RDP database [58]. To deal with variation
in sequences depth the OTU proportion were corrected using the zero-inflated
Gaussian distribution implemented in MetagenomeSeq [59].
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5.6. Statistical analyses
Data were compared using the non-parametric Wilcoxon Rank-Sum test (when
comparing two sample or matched samples) or the Kruskal-Wallis test. Differences
were considered significant with a p-value < 0.05. Treatment effects on the overall
microbial community structure was evaluated by generating the Bray-Curtis
dissimilarity between samples and clustering was visualized by using ordination
applying non-metric multidimensional scaling (NMDS) generated in the R vegan
package [60].
The microbial clustering was further evaluated with the analysis of similarity
(Anosim) [61] and tested for significance by 999 permutations with a 5%
significance level. Individual variation of selected microbes was displayed with the
Euclidean distance in the heatmap based on the log-transformed metagenomeSeq
normalized OTU counts.
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